Abstract：Objective To study the expression of lung tissue-specific protein,cytokeratin 19 and calcium binding protein A4 in peripheral blood nucleated cells of patients with non-small cell lung cancer.Methods Each of 60 patients with confirmed lung benign and non-small cell lung cancer treated at Jiangxi Chest Hospital from March 2018 to December 2019 were respectively selected as study group 1 and study group 2.Then 60 healthy people of the same age who received physical examination in Jiangxi Chest Hospital during the same period were selected as the control group.The positive expression of lung tissue-specific protein,cytokeratin 19 and calcium binding protein A4 in peripheral blood nucleated cells of the three groups were detected by fluorescence quantitative PCR,and the detection results were compared.Results The levels of lung tissue-specific protein and calcium binding protein in the study 1 group were higher than those in the control group,the differences were statistically significant(P<0.05).The level of lung tissue-specific protein in the study 2 group was higher than that in the study 1 group,the difference was statistically significant(P<0.05).Three genes of expression of lung tissue-specific protein,cytokeratin 19,and calcium-binding protein A4 in peripheral blood nucleocytes in the study 2 group were higher than that in the study 1 group,the differences were statistically significant(P<0.05).Three genes of expression of lung tissue-specific protein,cytokeratin 19,and calcium-binding protein A4 in peripheral blood nucleocytes in the study 1 group were higher than that in the control group,the differences were statistically significant(P<0.05).Conclusion The positive rates of lung tissue-specific protein,cytokeratin 19 and calcium binding protein A4 in peripheral blood nucleated cells of patients with nonsmall-cell lung cancer are significantly higher than those of patients with benign lung diseases and healthy people,which could be used as an important reference for the diagnosis and treatment of NSCLC.
Yao Y，Peng M，Shen Q，et al.Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples[J].Thorac Cancer，2019，10（2）：193-202.
Xibin Z，Chao Z，Jiayu L，et al.Clinical features and therapeutic options in non small cell lung cancer patients with concomitant mutations of EGFR，ALK，ROS1，KRAS or BRAF[J].Cancer Medicine，2019，8（6）：2858-2866.
William W，Ning W，Ravindra G，et al.Utilization trends and factors associated with ROS1 testing among advanced non small-cell lung cancer patients in US community practices[J].Clinical Lung Cancer，2020，6（9）：1016-1017.
京公网安备 11010502046607号